



MEDICAL SCHOOL AT HOUSTON

A part of The University of Texas Health Science Center at Houston

Pathology Diagnostic Laboratory

Newsletter

May, Edition B


2009

The Molecular Diagnostics Laboratory (MDL)

We chase the viral genomes for you

Introduction

The Molecular Diagnostics Laboratory (MDL) of the Department of Pathology & Laboratory Medicine under the leadership of its Director, Yu Bai, MD PhD, Assistant Professor, and in collaboration with Phoebe Mai, Medical Technologist, is fully accredited by the College of American Pathologist (CAP) and offers expertise in molecular pathology for diagnostic services and research collaboration. This includes provision of fast and accurate results for established diagnostic tests, implementation and development of new high-complexity tests to meet clinical needs and collaboration with clinical research.



Selected Examples of Services

Hybrid Capture 2 High-Risk HPV DNA Test – FDA approved In Vitro nucleic acid hybridization assay with signal amplification for the qualitative detection of thirteen high-risk types of human papillomavirus (HPV) DNA in cervical specimens. It is generally accepted that these viruses are predominantly sexually transmitted and that high-risk HPV types are a major recognized risk factor for the development of cervical cancer. In conjunction with clinical information derived from other diagnostic and screening tests, physical examinations and full medical history, HPV DNA Test is a great valuable contribution in patient-management decisions.

Aptima Combo2 CT/GC Assay – FDA-approved target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA from *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC). CT and GC infections are two of the most common sexually transmitted infections worldwide. This test aids in the diagnosis of chlamydial and/or gonococcal urogenital disease. This test can be done on a wide variety of patients' samples including endocervical, vaginal, male urethral swab specimens, PreservCyt liquid Pap specimens, and in female and male urine samples from symptomatic and asymptomatic individuals.

TruGene HIV-1 Genotyping: FDA-approved method for use in detecting HIV-1 genomic mutations (in the protease and part of the reverse transcriptase regions of HIV-1) that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring and treating HIV infection. This provides clinicians with a genetic map, which may guide physicians in making more informed treatment decisions, thereby improving patient outcome.

For more information contact:

Yu Bai, MD, PhD., Lab Director, 713-500-5339, or Phoebe Mai, Medical Technologist III, Molecular Diagnostics Laboratory, 713-500-5313